

Audit Review Table				
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2016; Date & Timestamp - 6/9/2017 3:14:06 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and Screening				
Adult BMI Assessment (aba)		76.16%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)				
<i>BMI Percentile</i>		58.76%	R	Reportable
<i>Counseling for Nutrition</i>		49.00%	R	Reportable
<i>Counseling for Physical Activity</i>		45.01%	R	Reportable
Childhood Immunization Status (cis)				
<i>DTaP</i>		76.16%	R	Reportable
<i>IPV</i>		88.30%	R	Reportable
<i>MMR</i>		87.20%	R	Reportable
<i>HiB</i>		87.42%	R	Reportable
<i>Hepatitis B</i>		88.30%	R	Reportable
<i>VZV</i>		87.42%	R	Reportable
<i>Pneumococcal Conjugate</i>		75.72%	R	Reportable
<i>Hepatitis A</i>		87.20%	R	Reportable
<i>Rotavirus</i>		75.28%	R	Reportable
<i>Influenza</i>		42.60%	R	Reportable
<i>Combination #2</i>		72.85%	R	Reportable
<i>Combination #3</i>		70.20%	R	Reportable
<i>Combination #4</i>		69.76%	R	Reportable
<i>Combination #5</i>		62.03%	R	Reportable
<i>Combination #6</i>		37.31%	R	Reportable
<i>Combination #7</i>		61.81%	R	Reportable
<i>Combination #8</i>		36.87%	R	Reportable
<i>Combination #9</i>		34.44%	R	Reportable
<i>Combination #10</i>		34.22%	R	Reportable
Immunizations for Adolescents (ima)				

<i>Meningococcal</i>		66.00%	R	Reportable
<i>Tdap</i>		82.34%	R	Reportable
<i>HPV</i>		19.21%	R	Reportable
<i>Combination #1</i>		65.12%	R	Reportable
<i>Combination #2</i>		18.32%	R	Reportable
Lead Screening in Children (lsc)		33.49%	R	Reportable
Breast Cancer Screening (bcs)		41.65%	R	Reportable
Cervical Cancer Screening (ccs)		52.55%	R	Reportable
Chlamydia Screening in Women (chl)				
<i>16-20 Years</i>		42.37%	R	Reportable
<i>21-24 Years</i>		50.83%	R	Reportable
<i>Total</i>		47.35%	R	Reportable
Effectiveness of Care: Respiratory				
Appropriate Testing for Children with Pharyngitis (cwp)	Y	63.78%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)		27.92%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y			
<i>Systemic Corticosteroid</i>		36.87%	R	Reportable
<i>Bronchodilator</i>		45.54%	R	Reportable
Medication Management for People With Asthma (mma)	Y			
<i>5-11 Years: Medication Compliance 50%</i>		52.28%	R	Reportable
<i>5-11 Years: Medication Compliance 75%</i>		22.80%	R	Reportable
<i>12-18 Years: Medication Compliance 50%</i>		39.90%	R	Reportable
<i>12-18 Years: Medication Compliance 75%</i>		20.19%	R	Reportable
<i>19-50 Years: Medication Compliance 50%</i>		58.76%	R	Reportable
<i>19-50 Years: Medication Compliance 75%</i>		33.20%	R	Reportable
<i>51-64 Years: Medication Compliance 50%</i>		72.45%	R	Reportable
<i>51-64 Years: Medication Compliance 75%</i>		40.82%	R	Reportable
<i>Total: Medication Compliance 50%</i>		55.99%	R	Reportable
<i>Total: Medication Compliance 75%</i>		29.39%	R	Reportable
Asthma Medication Ratio (amr)	Y			
<i>5-11 Years</i>		74.57%	R	Reportable

12-18 Years		61.34%	R	Reportable
19-50 Years		48.55%	R	Reportable
51-64 Years		55.80%	R	Reportable
Total		58.04%	R	Reportable
Effectiveness of Care: Cardiovascular				
Controlling High Blood Pressure (cbp)		55.60%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	63.86%	R	Reportable
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
<i>Received Statin Therapy: 21-75 Years (Male)</i>		56.65%	R	Reportable
<i>Statin Adherence 80%: 21-75 Years (Male)</i>		60.56%	R	Reportable
<i>Received Statin Therapy: 40-75 Years (Female)</i>		39.64%	R	Reportable
<i>Statin Adherence 80%: 40-75 Years (Female)</i>		56.82%	R	Reportable
<i>Received Statin Therapy: Total</i>		50.33%	R	Reportable
<i>Statin Adherence 80%: Total</i>		59.47%	R	Reportable
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
<i>Hemoglobin A1c (HbA1c) Testing</i>		82.56%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>		48.57%	R	Reportable
<i>HbA1c Control (<8.0%)</i>		41.94%	R	Reportable
<i>HbA1c Control (<7.0%)</i>			NR	Not Reported
<i>Eye Exam (Retinal) Performed</i>		51.21%	R	Reportable
<i>Medical Attention for Nephropathy</i>		87.42%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>		55.41%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y			
<i>Received Statin Therapy</i>		40.68%	R	Reportable
<i>Statin Adherence 80%</i>		51.56%	R	Reportable
Effectiveness of Care: Musculoskeletal				
Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	62.31%	R	Reportable
Effectiveness of Care: Behavioral				
Antidepressant Medication Management (amm)	Y			
<i>Effective Acute Phase Treatment</i>		50.56%	R	Reportable
<i>Effective Continuation Phase Treatment</i>		34.51%	R	Reportable

Follow-Up Care for Children Prescribed ADHD Medication (add)	Y			
<i>Initiation Phase</i>		51.16%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>		70.21%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y			
<i>30-Day Follow-Up</i>		58.27%	R	Reportable
<i>7-Day Follow-Up</i>		37.21%	R	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Y			
<i>30-Day Follow-Up</i>		56.38%	R	Reportable
<i>7-Day Follow-Up</i>		45.16%	R	Reportable
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence (fua)	Y			
<i>30-Day Follow-Up: 13-17 Years</i>		13.33%	R	Reportable
<i>7-Day Follow-Up: 13-17 Years</i>		4.44%	R	Reportable
<i>30-Day Follow-Up: 18+ Years</i>		17.78%	R	Reportable
<i>7-Day Follow-Up: 18+ Years</i>		11.16%	R	Reportable
<i>30-Day Follow-Up: Total</i>		17.69%	R	Reportable
<i>7-Day Follow-Up: Total</i>		11.04%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	78.02%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		46.00%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)		50.00%	NA	Small Denominator
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	47.81%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
<i>1-5 Years</i>		40.00%	NA	Small Denominator

6-11 Years		28.57%	R	Reportable
12-17 Years		31.86%	R	Reportable
Total		30.84%	R	Reportable
Effectiveness of Care: Medication				
Annual Monitoring for Patients on Persistent Medications (mpm)	Y			
ACE Inhibitors or ARBs		83.30%	R	Reportable
Digoxin		52.17%	NA	Small Denominator
Diuretics		84.70%	R	Reportable
Total		83.70%	R	Reportable
Effectiveness of Care:				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		1.57%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	88.26%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	28.51%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		70.15%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		3.53%	R	Reportable
12-17 Years		4.11%	R	Reportable
Total		3.81%	R	Reportable
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
20-44 Years		68.39%	R	Reportable
45-64 Years		79.13%	R	Reportable
65+ Years		89.34%	R	Reportable
Total		73.10%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
12-24 Months		93.25%	R	Reportable
25 Months - 6 Years		82.02%	R	Reportable

7-11 Years		84.82%	R	Reportable
12-19 Years		83.89%	R	Reportable
Annual Dental Visit (adv)	Y			
2-3 Years		51.12%	R	Reportable
4-6 Years		67.17%	R	Reportable
7-10 Years		70.71%	R	Reportable
11-14 Years		66.84%	R	Reportable
15-18 Years		56.43%	R	Reportable
19-20 Years		37.77%	R	Reportable
Total		61.78%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y			
Initiation of AOD Treatment: 13-17 Years		36.72%	R	Reportable
Engagement of AOD Treatment: 13-17 Years		7.91%	R	Reportable
Initiation of AOD Treatment: 18+ Years		36.26%	R	Reportable
Engagement of AOD Treatment: 18+ Years		14.56%	R	Reportable
Initiation of AOD Treatment: Total		36.27%	R	Reportable
Engagement of AOD Treatment: Total		14.39%	R	Reportable
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care		75.50%	R	Reportable
Postpartum Care		58.06%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y			
1-5 Years		33.33%	NA	Small Denominator
6-11 Years		60.98%	R	Reportable
12-17 Years		57.81%	R	Reportable
Total		58.33%	R	Reportable
Utilization				
Frequency of Ongoing Prenatal Care (fpc)				
<21 Percent		11.70%	R	Reportable
21-40 Percent		8.61%	R	Reportable
41-60 Percent		9.93%	R	Reportable
61-80 Percent		13.91%	R	Reportable
81+ Percent		55.85%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)				
0 Visits		3.99%	R	Reportable

1 Visit		2.44%	R	Reportable
2 Visits		3.57%	R	Reportable
3 Visits		5.61%	R	Reportable
4 Visits		9.97%	R	Reportable
5 Visits		16.07%	R	Reportable
6+ Visits		58.35%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		55.84%	R	Reportable
Adolescent Well-Care Visits (awc)		32.25%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NR	Not Reported
Ambulatory Care: Disabled (ambc)			NR	Not Reported
Ambulatory Care: Other (ambd)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NR	Not Reported
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N		NQ	Not Required
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N		NQ	Not Required
Identification of Alcohol and Other Drug Services: Other (iadd)	N		NQ	Not Required
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N		NQ	Not Required
Mental Health Utilization: Disabled (mptc)	N		NQ	Not Required
Mental Health Utilization: Other (mptd)	N		NQ	Not Required
Antibiotic Utilization: Total (abxa)	Y		R	Reportable

Antibiotic Utilization: Dual Eligibles (abxb)	N		NQ	Not Required
Antibiotic Utilization: Disabled (abxc)	N		NQ	Not Required
Antibiotic Utilization: Other (abxd)	N		NQ	Not Required
Standardized Healthcare-Associated Infection Ratio (hai)			R	Reportable
Health Plan Descriptive				
Board Certification (bcr)			UN	Unaudited
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NR	Not Reported
Enrollment by Product Line: Disabled (enpc)			NR	Not Reported
Enrollment by Product Line: Other (enpd)			NR	Not Reported
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			NR	Not Reported
Race/Ethnicity Diversity of Membership (rdm)			NR	Not Reported
Total Membership (tlm)			R	Reportable
Measures Collected using Electronic				
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Inclusion in ECDS: Total</i>			NR	Not Reported
<i>Utilization of PHQ-9: Total</i>			NR	Not Reported
Depression and Remission or Response for Adolescents and Adults (drr)				
<i>EDCS Coverage: Total</i>			NR	Not Reported
<i>Follow-up PHQ-9: Total</i>			NR	Not Reported
<i>Depression Remission: Total</i>			NR	Not Reported
<i>Depression Response: Total</i>			NR	Not Reported